Patents Assigned to Quest Diagnostics
  • METHODS FOR DETECTING CHROMOGRANIN A BY MASS SPECTROMETRY
    Publication number: 20220163494
    Abstract: Provided are methods for detecting chromogranin A by mass spectrometry. In another aspect, provided herein are methods for quantitating chromogranin A by mass spectrometry. In another aspect, provided herein are methods for prognosis of or measuring the size of neuroendocrine tumors by mass spectrometry.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 26, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Darren Weber, Michael P. Caufield, Michael McPhaul, Scott Goldman, Nigel Clarke
  • Mass spectrometric quantitation assay for metabolites of leflunomide
    Patent number: 11333673
    Abstract: Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 17, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Karin O. Thomassian
  • METHODS FOR DETECTING LEGIONELLA
    Publication number: 20220145367
    Abstract: The present disclosure provides methods for determining whether a patient exhibiting pneumonia-like symptoms will benefit from treatment with therapeutic agents that inhibit Legionella sp. These methods are based on detecting Legionella sp. and/or Legionella pneumophila in a biological sample. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 12, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Erik P. Johnson
  • Vitamin B2 detection by mass spectrometry
    Patent number: 11300559
    Abstract: Methods are described for measuring the amount of a vitamin B2 in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying vitamin B2 in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: April 12, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Changming Yang, Sum Chan
  • NUCLEIC ACID DETECTION COMBINING AMPLIFICATION WITH FRAGMENTATION
    Publication number: 20220098679
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 31, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather R. SANDERS, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
  • RNA ISOLATION FROM SOLUBLE URINE FRACTIONS
    Publication number: 20220090049
    Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather SANDERS, Hai-Rong Li
  • Container for a specimen and method of using same
    Patent number: 11278904
    Abstract: A container for a specimen includes a container configured to receive a specimen for evaluation, a first label disposed on the container and having identifying information, and a second label disposed on the container so as to entirely cover at least all perimeter edges of the first label. The second label includes a viewing portion that allows for evaluation of the specimen and an identification portion configured to receive identifying information. Methods for using the container for a specimen are also disclosed.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: March 22, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Daniel E. Carty, Fredric Solomon
  • Mass spectrometric determination of non-derivatized, non-metabolized vitamin D
    Patent number: 11280799
    Abstract: The invention relates to the detection of non-metabolized vitamin D. In a particular aspect, the invention relates to methods for detecting underivatized non-metabolized vitamin D by mass spectrometry.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: March 22, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Brett Holmquist, Nigel Clarke
  • Methods for detecting estrone by mass spectrometry
    Patent number: 11280798
    Abstract: Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: March 22, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Mildred M. Goldman, Richard E. Reitz
  • BCR-ABL variants
    Patent number: 11275088
    Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: March 15, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Maher Albitar
  • METHODS FOR QUANTITATION OF INSULIN AND C-PEPTIDE
    Publication number: 20220042971
    Abstract: Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Application
    Filed: April 19, 2021
    Publication date: February 10, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Dov Shiffman, Carmen Tong, James J. Devlin, Michael J. McPhaul
  • DETECTION OF GENE FUSIONS BY INTRAGENIC DIFFERENTIAL EXPRESSION (IDE) USING AVERAGE CYCLE THRESHOLDS
    Publication number: 20220042110
    Abstract: Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene. The average expression of the 5? portion of the target gene is compared with the average expression of the 3? portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 10, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Shih-Min CHENG
  • UNIVERSAL SANGER SEQUENCING FROM NEXT-GEN SEQUENCING AMPLICONS
    Publication number: 20220033901
    Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 3, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
  • Methods for detecting chromogranin a by mass spectrometry
    Patent number: 11231401
    Abstract: Provided are methods for detecting chromogranin A by mass spectrometry. In another aspect, provided herein are methods for quantitating chromogranin A by mass spectrometry. In another aspect, provided herein are methods for prognosis of or measuring the size of neuroendocrine tumors by mass spectrometry.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 25, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Darren Weber, Michael P. Caufield, Michael McPhaul, Scott Goldman, Nigel Clarke
  • NUCLEIC ACID ANALYSIS USING EMULSION PCR
    Publication number: 20220010378
    Abstract: The present invention provides methods for analyzing large nucleic acids including chromosomes and chromosomal fragments. In one aspect, the present invention provides a method of nucleic acid analysis comprising the steps of (a) obtaining a sample of nucleic acid comprising at least one chromosome or fragment greater than about 1,000 base pairs in length and containing a target region; (b) creating an emulsion in which each drop of the emulsion contains an average of between about 0-2, 0-1.75, 0-1.5, 0-1.0, 0-0.75, 0-0.5, or fewer chromosomes or fragments of step (a), (c) performing emulsion PCR, (d) quantifying the number of emulsion droplets containing amplified nucleic acid from the target region; (e) calculating the ratio of droplets containing amplified nucleic acid from the target region to total droplets; and (f) comparing the ratio of step (e) to a reference ratio representing a known genotype.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 13, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Charles M. STROM
  • QUANTITATION OF INSULIN BY MASS SPECTROMETRY
    Publication number: 20210382076
    Abstract: Methods are described for determining the amount of insulin in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying insulin in a biological sample utilizing purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Application
    Filed: August 20, 2021
    Publication date: December 9, 2021
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Zhaohui CHEN, Nigel CLARKE
  • RNA isolation from soluble urine fractions
    Patent number: 11193120
    Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: December 7, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Hai-Rong Li
  • METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS
    Publication number: 20210363569
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Application
    Filed: June 7, 2021
    Publication date: November 25, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Erik P. Johnson, Dale A. Schwab
  • Mass spectrometric determination of eicosapentaenoic acid and docosahexaenoic acid
    Patent number: 11181537
    Abstract: The invention relates to the detection of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). In a particular aspect, the invention relates to methods for detecting DHA and EPA by mass spectrometry and kits for carrying out such methods.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: November 23, 2021
    Assignee: Quest Diagnostics Investments Incoporated
    Inventors: Scott M. Goldman, Julie A. Neidich
  • BCR-ABL1 splice variants and uses thereof
    Patent number: 11162142
    Abstract: The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 2, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Wanlong Ma